News Releases

BASEL, Switzerland & IRVINE, Calif. --(BUSINESS WIRE)--Nov. 19, 2018-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced Chief Executive Officer Keith A.

BASEL, Switzerland & IRVINE, Calif. --(BUSINESS WIRE)--Nov. 12, 2018-- Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing therapies for urologic conditions, today reported financial results for the three and six months ended September 30, 2018 and

More than 1,500 patients enrolled in international Phase 3 clinical trial EMPOWUR, exceeding recruitment target Top-line efficacy and safety data from Phase 3 trial expected by the end of March 2019 BASEL, Switzerland & IRVINE, Calif. --(BUSINESS WIRE)--Nov.

BASEL, Switzerland & IRVINE, Calif. --(BUSINESS WIRE)--Nov. 5, 2018-- Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced it will report 2018 second fiscal quarter financial results after the

BASEL, Switzerland & IRVINE, Calif. --(BUSINESS WIRE)--Nov. 1, 2018-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced the publication of positive results from the international Phase 2b study

BASEL, Switzerland and IRVINE, Calif. , Sept. 26, 2018 /PRNewswire/ -- Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing therapies for urologic conditions, today announced the pricing of its initial public offering of 10,000,000 common shares at

Kyorin secures first commercial approval for vibegron Vibegron will be a new treatment option in Japan, where an estimated 10.4 million people suffer from overactive bladder symptoms defined as the sudden urge to urinate, frequent urination and urge incontinence BASEL, Switzerland and IRVINE,

There are no currently available FDA-approved gene therapy treatments for overactive bladder Urovant expects to initiate Phase 2 hMaxi-K study in 2019 BASEL, Switzerland and IRVINE, Calif., August 28, 2018/PRNewswire – Urovant Sciences, a clinical-stage biopharmaceutical company focused on

BASEL, Switzerland and IRVINE, Calif., July [9], 2018 /PRNewswire/ — Urovant Sciences, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced the appointments of Sef Kurstjens, M.D., Ph.D.

Cornelia Haag-Molkenteller, former VP and Therapeutic Area Head, Clinical Development, for Urology, Women’s Health, and Internal Medicine at Allergan, joins as Chief Medical Officer Michael McFadden, former SVP for Commercial at Avanir, joins as Chief Commercial Officer Bryan Smith, former Senior